PD732 - EFFECTS OF CURCUMIN SUPPLEMENTATION ON P53 LEVELS IN TUMOR CELLS AND CLINICAL OUTCOMES IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER

Linked sessions

PD732

EFFECTS OF CURCUMIN SUPPLEMENTATION ON P53 LEVELS IN TUMOR CELLS AND CLINICAL OUTCOMES IN PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER

A. A. Rueda Escalona1,2, A. García Yepes2,3, O. Medina-Contreras4, A. M. García Carrancá5, D. Castro-Eguiluz2,6,*

1Master’s in Medical Sciences Program, Universidad Anáhuac Mexico, Huixquilucan, 2Department of Clinical Research, Instituto Nacional de Cancerología, 3Department of Molecular Biomedicine, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, 4Epidemiology, Endocrinology & Nutrition Research Unit, Hospital Infantil de México Federico Gómez, 5Biomedical Research in Cancer Unit, Instituto de Investigaciones Biomédicas UNAM, 6Investigadores por México, Secretaría de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI), Mexico City, Mexico

 

Rationale: Cervical cancer (CC) cells often show reduced p53 expression, favoring malignant progression. Curcumin can restore p53 levels in vitro, but its effects in CC patients and its optimal dose remain unclear. We evaluated the effects of different curcumin doses on p53 levels in cervicovaginal samples (CVS) from patients with locally advanced CC (LACC) and on their clinical outcomes.

Methods: In this pilot study, patients with LACC treated at the National Cancer Institute of Mexico received 1g, 3g, or 6g of curcumin daily, with or without 10mg piperine, from 2 weeks before until completion of chemoradiotherapy (CRT) (~12 weeks). CVS were collected to quantify p53 by ELISA. Treatment response and disease-free survival (DFS) were assessed.

Results: 30 patients were recruited (5 per group), with a median age of 42±8 years; 77.8% had stage IIIC1 disease. Baseline functional status and treatment characteristics were similar across groups. Curcumin was well tolerated, with no adverse effects beyond those of CRT. Overall, p53 levels did not differ between groups or change significantly over time; only the 1g curcumin-alone group showed a modest increase in p53 (~10%), whereas 1g curcumin + piperine showed the greatest decrease (−23%). All patients receiving 6g curcumin (with or without piperine) achieved complete response and remained disease-free at 30 months, whereas 20–70% of patients in the 1g and 3g groups had stable or progressive disease and the poorest DFS. Curcumin dose was associated with improved DFS (HR 0.62, 95% CI 0.39–0.9).

Conclusion: Curcumin supplementation up to 6g daily is safe but does not increase p53 levels in CVS from patients with LACC. However, 6g of curcumin, with or without piperine, is associated with complete response and 100% DFS at 30 months, warranting larger trials to clarify its mechanisms.

Disclosure of Interest: None declared